LZYY(SH:603368) Sou Hu Cai Jing·2025-10-25 18:46Core Viewpoint - Liu Pharmaceutical Group (603368) is focusing on AI applications in healthcare and has made significant progress in its clinical trials and stock option plans [1][2][3] Company Announcements - Liu Pharmaceutical Group held its semi-annual performance briefing on October 20, 2025, where it introduced an "AI + Healthcare" full-process service plan aimed at enhancing AI applications in both hospital and supply chain settings [1] - The company announced that its investee, SIF001, has entered Phase I clinical trials in the United States, expected to be completed by early 2026 [1][3] - The company has completed the registration of its 2025 stock option incentive plan, involving 286.32 million options granted to 107 individuals, with a grant price of 18.12 yuan per share [2][3] Financial Performance - As of October 24, 2025, Liu Pharmaceutical Group's stock closed at 18.43 yuan, down 0.65% from the previous week, with a total market capitalization of 7.32 billion yuan [1] - The company has repurchased a total of 8.1079 million shares, with a total expenditure of approximately 148.46 million yuan as of September 30, 2025 [2][3]